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Background: Nasopharyngeal carcinoma (NPC) is a frequent head and neck cancer in southern China and
Southeast Asia. The majority of NPC patients are managed by radiation oncologists, medical oncologists and head
and neck surgeons. Actually, neurosurgical interventions are warranted under specific circumstances. In this article,
we described our experience as neurosurgeons in the management of NPC patients.
Methods: Medical records of NPC patients who received neurosurgical procedure at Sun Yat-sen University Cancer
Center were reviewed.
Results: Twenty-seven patients were identified. Among 27 cases, neurosurgical procedures were performed in 18
(66.7%) with radiation-induced temporal necrosis, 2 (7.4%) with radiation-induced sarcoma, 4 (14.8%) with
synchronous NPC with primary brain tumors, 2 (7.4%) with recurrent NPC involving skull base, and 1 (3.7%) with
metachronous skull eosinophilic granuloma, respectively. The diagnosis is challenging in specific cases and initial
misdiagnoses were found in 6 (22.2%) patients.
Conclusions: For NPC patients with intracranial or skull lesions, the initial diagnosis can be occasionally difficult
because of the presence or a history of NPC and related treatment. Unawareness of these entities can result in
misdiagnosis and subsequent improper treatment. Neurosurgical interventions are necessary for the diagnosis and
treatment for these patients.
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Nasopharyngeal carcinoma (NPC) is one of the most
prevalent malignancies in southern China and Southeast
Asia. In a Chinese endemic area, the incidence rate of
NPC reaches as high as 27.2 per 100,000 person-years in
men [1]. In addition, NPC is more significantly frequent
in Chinese immigrants in the United States [2]. Radio-
therapy remains the mainstay treatment for NPC due to
the radiosensitivity of the disease. In addition, NPC has
been demonstrated to have a high response rate to* Correspondence: chenzp57@mail.sysu.edu.cn
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reproduction in any medium, provided the ormultiple chemotherapeutic agents. The combination of
chemotherapy with radiotherapy results in a decrease in
distant metastases and improvement of locoregional
control rate as well as overall survival [3]. Moreover, sal-
vage surgery is indicated and beneficial for selected
patients with local recurrent disease [4]. Therefore, the
majority of patients with NPC are managed by radiation
oncologists, medical oncologists, head and neck sur-
geons, or otolaryngologists. Occasionally, intracranial or
skull lesions are found in NPC patients in the course of
disease. The imaging manifestation of these lesions can
be deceiving, which makes the initial diagnosis difficult.
Neurosurgical procedures are therefore warranted for
both diagnosis and treatment. In this article, we presentThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ical role in the management of patients with NPC.
Methods
The current study was approved by the ethics committee
of Sun Yat-sen University Cancer Center. Written in-
formed consent was obtained from all the patients. We
searched the institutional database of patients surgically
treated in the Department of Neurosurgery between
January 1999 and August 2012. Patients with a histo-
logical diagnosis or a history of NPC were identified and
clinical records were reviewed.
Results
A total of 27 cases were identified. Among these patients
were eighteen (66.7%) with radiation-induced temporal
necrosis (RITN), two (7.4%) with radiation-induced sar-
coma (RIS), four (14.8%) with synchronous NPC with
primary brain tumors, two (7.4%) with recurrent NPC
involving the base of the skull, and one (3.7%) with
metachronous skull eosinophilic granuloma (EG).
Radiation-induced temporal necrosis
Eighteen patients (age 37 to 63 years; mean 49.6 years)
with RITN after radiotherapy for NPC received neuro-













1 42/M T4N3M0 No 82
2 37/M T4N1M0 No 80
3 46/F T2N1M0 No 70
4 60/F T3N1M0 No 68
5 57/M T2N0M0 No 70
6 46/M T3N0M0 Yes 70 + 65
7 56/M T3N1M0 No 70
8 42/M T2N0M0 No 70
9 49/M T2N0M0 No 68
10 63/M T1N0M0 No 68
11 39/M T2N0M0 Yes 68 + 60
12 37/M T1N0M0 No 70
13 58/M T1N0M0 Yes 60 + 66
14 59/M T4N0M0 No 75
15 47/M T3N0M0 Yes 70 +64*
16 59/M T4N0M0 No 74
17 50/M T3N0M0 No 72
18 45/M T4N0M0 No 66
NPC, nasopharyngeal carcinoma, RITN, radiation-induced temporal necrosis, TNM, tu
radiotherapy, *dose for repeated radiotherapy.dose was 70.5 Gray (Gy), (range 60 to 82 Gy). Four pa-
tients received repeated radiotherapy for recurrent NPC,
with a dose ranging from 60 to 66 Gy. The mean latency
of RITN was 6.3 years. Among the 18 patients, headache
was the most common symptom, being observed in 16
patients. Fourteen patients had impaired memory, ten
had vertigo, seven had neurological deficits, and one had
a seizure. RITN presented on magnetic resonance (MR)
images as a nodule with heterogeneous enhancement
(Figure 1a and b) in nine cases and as obvious cystic for-
mation (Figure 1c and d) in the other nine patients. Two
out of nine patients with heterogeneously enhanced
RITN had been initially diagnosed at the local hospital
as having malignant glioma, and were then referred to
our institution. Corticosteroid treatment failed and pro-
gressive increased intracranial pressure was observed in all
cases. Neurosurgical resection was applied through the
temporal approach. The mean postoperative follow up was
53.1 months, ranging from 5 to 114 months. One patient
(patient 13) died from exhaustion 2 months after the oper-
ation and one (patient 17) died from lung cancer 40
months after treatment for RITN. One patient (patient 6)
suffered from progressive radiation-induced necrosis in the
contralateral temporal lobe and underwent surgery. No re-
currence of necrotic lesions was observed and preoperative







9 Right 5 Improved
7 Left 6 Improved
7 Right 23 Improved
8 Right 22 Improved
5 Right 45 Improved
* 8 Right 53 Resection of RITN in the left
side at 39 mo, improved
7 Right 64 Improved
7 Left 57 Improved
8 Left 65 Improved
6 Right 55 Improved
* 3 Left 99 Improved
6 Right 87 Improved
* 1 Left 2 Died of exhaustion
5 Right 114 Improved
5 Right 63 Improved
5 Left 62 Improved
9 Left 40 Died of unrelated disease
8 Left 94 Improved
mor, node, metastasis, y, year, m, month, Gy, Gray, M, male, F, female, RT,
Figure 1 Radiation-induced temporal necrosis (RITN) presented on magnetic resonance (MR) images. RITN presented as a
heterogeneously enhanced nodule (arrow in a: axial T2-weighted MR image; b: axial contrast-enhanced MR image) or cystic formation
(arrow in c: axial T2-weighted MR image; d: axial contrast-enhanced MR image). Bleeding could be occasionally found in cystic RITN
(arrowhead in c and d).
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brain tumor
NPC was simultaneously diagnosed with glioma in two
patients (patients 19 and 20, Table 2, Figure 2) and with
meningioma involving the anterior skull base in two pa-
tients (patients 21 and 22, Table 2, Figure 3), respect-
ively. One patient (patient 20) had a family history of












19 30/M T3N2M0 Left frontal lobe/GBM C
c
20 37/M T1N0M0 Left frontal lobe/WHO grade II
astrocytoma
R
21 45/M T2N0M0 Sphenoidal sinus, anterior and
middle skull base/meningioma
R
22 68/M T4N2M0 Anterior skull base/meningioma C
c
NPC, nasopharyngeal carcinoma, TNM, tumor, node, metastasis, M, male mo, monthand one of his children was diagnosed with acute
lymphoblastic leukemia. NPC was detected in all four
patients by nasopharyngoscopy and histologically con-
firmed by biopsy. MR scanning revealed the coexistence
of an intracranial mass. Patient 19 was initially diag-
nosed as having NPC with intracranial metastasis and
patient 21 as having NPC with invasion of the skull base;
both were diagnosed at the local hospital. All fourbrain tumor























Total removal 24 Survival
without
recurrence
, GBM, glioblastoma multiforme, WHO, World Health Organization.
Figure 2 Synchronous nasopharyngeal carcinoma (NPC) with glioma. A 30-year old man (patient 19) suffered from headache and nasal
obstruction for 6 months. On magnetic resonance (MR) images, a mass in the left lateral side and the roof of nasopharynx (arrowhead in a and
b) was found. Moreover, a heterogeneously enhanced lesion was demonstrated in the left frontal lobe (arrow in a and b). Histological diagnosis
was undifferentiated non-keratinizing carcinoma for the mass in the nasopharynx, and glioblastoma multiforme for the left frontal lobe lesion. A
37-year old man (patient 20) presented with epistaxis for 2 months. The MR scan demonstrated a mass in the right lateral side and the roof of
the nasopharynx (arrows in c: axial contrast-enhanced MR). In addition, a left frontal lesion with hypodensity on T1-weighted images and
hyperintensity on T2-weighted images (arrows in d: axial T2-weighted MR), but without gadolinium enhancement, was synchronously found on
the MR scan. Endoscopic biopsy revealed a non-keratinizing NPC. Subtotal resection of the left frontal lesion was achieved and postoperative
histological examination established the diagnosis of World Health Organization grade II astrocytoma.
Sai et al. World Journal of Surgical Oncology 2013, 11:227 Page 4 of 12
http://www.wjso.com/content/11/1/227patients received microneurosurgery followed by treat-
ment for NPC. Total removal was achieved in two pa-
tients with meningioma and subtotal removal in two
with glioma. In all four patients, NPC was treated with
radiotherapy with or without chemotherapy. Glioma in
two patients was also treated with radiation and adju-
vant chemotherapy. The follow up ranged from 10 to
79 months. Two patients with meningioma had no re-
currence of NPC or intracranial tumor. One patient
(patient 19) with glioblastoma multiforme (GBM) died
10 months after the initial diagnosis because of
ventricle dissemination. The other patient with World
Health Organization (WHO) grade II astrocytoma
(patient 20) experienced malignant transformation of
the tumor and recurrence.
Radiation-induced sarcoma
Two cases of RIS (Table 3) were identified in this series
according to the diagnosis criteria defined by Cahan [5].
Both patients were men. The radiation dose was 70 Gyfor NPC in patient 23 and 68 Gy in patient 24. The
latency of RIS after radiotherapy was 119 months for pa-
tient 23 (Figure 4) and 117 months for patient 24.
Subtotal resection was achieved because of the extensive
invasion to adjacent structures in the skull base. Post-
operative radiotherapy was administered for both pa-
tients and chemotherapy was also given for patient 24.
Patient 23 was followed up for 13 months and local
recurrence was observed 7 months after initial diagnosis.
The patient was still alive but refused any further treat-
ment. Patient 24 died of recurrent RIS 6 months after
initial diagnosis.
Recurrent nasopharyngeal carcinoma involving the
skull base
We reported two cases with recurrent NPC involving
the base of the skull, with one in the cerebellopontine
angle (CPA) and the other in the mastoid antrum
(Table 3). A 43-year-old female patient (patient 25,
Figure 5) manifested with double vision and right facial
Figure 3 Synchronous nasopharyngeal carcinoma (NPC) with meningioma in the anterior and middle base of the skull. A 45-year old
man (patient 21) presented with hearing impairment in the right ear and dizziness for 10 days. The magnetic resonance (MR) scan demonstrated
a homogeneously enhanced mass involving the sphenoidal sinus, anterior skull base and right middle skull base (arrow heads in a, b and c:
contrast-enhanced MR). A lesion in the left lateral side of the nasopharynx (arrows in a and b: coronal contrast-enhanced MR) was also identified.
Endoscopic biopsy of the nasopharyngeal lesion (arrows in d: endoscopic view) and sphenoidal mass was performed. Histological examination
revealed the diagnosis of NPC with strong positive immunohistochemisty staining for P63 and CK in the nasopharynx (e: hematoxylin and eosin
staining, ×200) and meningioma immunopositive for epithelial membrane antigen (EMA) and vimentin but negative for CK and Epstein-Barr
virus-encoded RNA in situ hybridization (EBER ISH) in the sphenoidal sinus (f: hematoxylin and eosin staining, ×200).
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for NPC. Physical examination revealed palsy of the
right abducens and facial nerve, right trigeminal-
distribution facial hypesthesia, and ataxia. MR demon-
strated a marked contrast-enhanced lesion in the right
CPA with enlargement of the right internal auditory
meatus. The lesion was radiologically diagnosed as an
acoustic neuroma. Because the growth pattern was not
typical of an acoustic neuroma, 18F-fluorodeoxyglucose
positron emission tomography (18F -FDG PET) was












23 25/M T4N1M0 Radiation-induced
sarcoma
24 42/M T2N1M0 Radiation-induced
sarcoma
25 39/F T1N2M0 NPC recurrence in the
cerebellopontine angle
26 55/M T4N1M0 Mastoid recurrence of
NPC
27 44/M T2N2M0 Metachronous skull
eosinophilic granuloma
NPC, nasopharyngeal carcinoma: RITN, radiation-induced temporal necrosis; M, mal18F-FDG in the lesion and in the neck lymph node. Inva-
sion of NPC into the base of the skull was therefore
suspected. The patient underwent total removal of the
mass through the retrosigmoid approach and postopera-
tive histological examination revealed undifferentiated
NPC. Postoperative radiotherapy and chemotherapy was
administered for this patient. The patient was followed
up for 23 months and no recurrence was found. Another
57-year-old male patient (patient 26, Figure 6) had previ-
ous treatment of NPC 2 years before imaging follow up



























14 Resection of frontal lesion 7 Stable
e; y, year; mo, month.
Figure 4 Radiation-induced sarcoma in a patient with nasopharyngeal carcinoma (NPC). A 25-year-old man (patient 23) had undergone
irradiation with a total dose of 70 Gy for undifferentiated NPC (arrow in a: computed tomography (CT) scan). Approximately 10 years after
radiotherapy, he presented with pain in the right temporal region and exophthalmus of his right eye. Magnetic resonance (MR) imaging
demonstrated a contrast-enhanced lesion in the right temporal region with intracranial and orbital invasion (arrow in b: axial contrast-enhanced
MR image).One month later, the preoperative CT scan revealed significant enlargement of the lesion (arrow in c). Subtotal resection was
performed and postoperative histological examination showed nests and sheets of pleomorphic malignant tumor cells with scattered osteoid
formation, consistent with an osteosarcoma (d: hematoxylin and eosin staining, ×100).
Sai et al. World Journal of Surgical Oncology 2013, 11:227 Page 6 of 12
http://www.wjso.com/content/11/1/227lesion had been treated at the local hospital as mastoid-
itis but no improvement was observed. 18F-FDG PET
was performed on this patient at our institution and
demonstrated increased uptake of 18F-FDG. Radiation-
induced temporal bone malignancy was suspected.
Biopsy of the mastoid lesion was performed. A histo-
logical diagnosis of NPC was confirmed. The patient then
received radiotherapy for the mastoid recurrence of NPC.
The patient is still alive after 37-months of follow up.
Metachronous skull eosinophilic granuloma
A 45-year-old male patient (patient 27, Table 3, Figure 7)
had a tender palpable mass in his frontal bone and pain
for 1 month. Radiography of the skull demonstrated two
bony erosions in his frontal and occipital bone. These two
lesions were contrast-enhanced on the MR image. Bone
scintigraphy using Tc-99 m methylene diphosphonate
(MDP) revealed increased uptake of the nuclide by the
frontal lesion. The patient had been diagnosed with NPC
16 months before and had received chemotherapy and radi-
ation. No osteolytic lesion was detected in the skull by the
nuclide bone scan at that time. The patient was initiallydiagnosed as having skull metastasis from NPC. History of
cancer was found in his family; his maternal uncle had been
diagnosed with NPC, his father died of renal cancer and
his uncle died of liver cancer. On admission, no recur-
rence of NPC was found. Resection of the frontal lesion
was performed and the postoperative histological diagno-
sis was EG.
Discussion
Although uncommon in western countries, NPC is a fre-
quent head and neck cancer in southern China and
Southeast Asia. NPC is sometimes referred to as Can-
tonese cancer because the incidence of NPC in a specific
region in Guangdong province is 25 times higher than
that in the rest of the world. Chinese emigrants and
their family members still have a high risk of NPC. The
striking regional distribution has been found to be asso-
ciated with the extensive consumption of salted fish and
preserved vegetables in the endemic areas [6]. More
importantly, a recent genome-wide association study re-
vealed the association of NPC with the HLA-A region,
suggesting the influence of genetic factors in the etiology
Figure 5 Recurrent nasopharyngeal carcinoma (NPC) in the cerebellopontine angle (CPA). A homogeneously enhanced lesion with clear
demarcation in the right CPA (arrows in a: T2-weighted magnetic resonance (MR) image and arrows in b: contrast-enhanced MR) was found
(patient 25) 4 years after irradiation for NPC. Enlargement of the right internal meatus (arrow head in a: T2-weighted MR image) was also
demonstrated. The lesion (arrows in c: 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET)) and the neck lymph node had
increased uptake of 18F-FDG. Postoperative histological examination revealed an undifferentiated non-keratinizing carcinoma immunopositive for
CK and P63 and positive for Epstein-Barr virus-encoded RNA in situ hybridization (EBERs ISH) (arrows in d: positive EBERs ISH in tumor cell
nuclei, ×100).
Sai et al. World Journal of Surgical Oncology 2013, 11:227 Page 7 of 12
http://www.wjso.com/content/11/1/227of NPC [7]. In our institution, more than 2,000 NPC
patients were treated every year. The majority of these
patients were managed by radiation oncologists, medical
oncologists and head and neck surgeons. With a large
NPC patient population, we had the opportunity to
identify a series of 27 cases, for which neurosurgical in-
terventions were necessary. The entities presented in the
current article included (1) late stage RITN; (2) RIS; (3)
simultaneously diagnosed NPC and brain tumors; (4)
recurrent NPC with the involvement of the skull base;
and (5) metachronous skull EG. Although uncommon,
these cases are of great clinical significance. The
presence or history of NPC or the treatment-related
complications makes it difficult initially to accurately
diagnose the intracranial or skull lesions in specific
cases. Unawareness of these entities can result in delayed
diagnosis, or even misdiagnosis and subsequent impropertreatment. Among twenty-seven cases, six (22%) were
initially misdiagnosed. Neurosurgical interventions are
indispensible for the accurate diagnosis and treatment
of intracranial or skull lesions in these NPC patients.
RITN is a severe late sequel for NPC patients after
radiotherapy and composes the major disease entity in
our series, accounting for 66.7% of all cases. The tem-
poral lobes are anatomically adjacent to the nasopharyn-
geal cavity and are therefore inevitably delineated in the
irradiation field. The development of RITN has been
suggested to be associated with the total dose of the ex-
ternal beam radiation, the fraction schedule, and possibly
with the chemotherapy administration [8,9]. Radiation-
induced progressive damage to vessel endothelium and
migration of inflammatory cells are proposed to be the
mechanisms underlying RITN [10]. On MR images, the
early stage of RITN manifests as patchy or nodular
Figure 6 Recurrent nasopharyngeal carcinoma (NPC) in the mastoid antrum. The imaging follow up with computed tomography (CT)
demonstrated a soft tissue mass (arrow in a: CT scan) in the right mastoid antrum of patient 26, who had been diagnosed and treated for NPC 2
years before. Magnetic resonance (MR) imaging showed an enhanced lesion in the right mastoid antrum (arrow in b and c: contrast-enhanced
MR). Histological examination after biopsy revealed an undifferentiated non-keratinizing carcinoma, consistent with NPC (d: strong cytoplasmic
staining of CK in tumor cells, ×100; arrows in e: positive Epstein-Barr virus-encoded RNA in situ hybridization (EBERs ISH) in tumor cell
nuclei, ×100).
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cystic formation or heterogeneous necrotic enhancement
can be observed. Cystic RITN is usually not difficult to
diagnose, and should be distinguished from a temporal
abscess. But as for heterogeneously enhanced temporal
lesions in irradiated patients with NPC, it is sometimes
challenging to establish the accurate diagnosis based
on MR alone. Without consideration of the history of
irradiated NPC, a radiologist or a neurosurgeon mayFigure 7 Metachronous skull eosinophilic granuloma. Patient 27 prese
treated for nasopharangeal carcinoma. Radiography of the skull demonstra
The lesions were contrast-enhanced on the magnetic resonance image (ar
cells and eosinophils with positive immunohistochemistry for S100 and CDdiagnose primary malignant brain tumors in these cases.
In our series, two of nine patients with heterogeneously
enhanced RITN had been radiologically diagnosed as hav-
ing malignant glioma. 18F-FDG PET has been employed
complementary to MR imaging, with the assumption of its
superiority to distinguish necrosis from an actively prolifer-
ating malignant tumor, by evaluating the metabolic level in
the lesion. However, we and other groups found that 18F-
FDG can be significantly taken up by some necrotic lesions,nted with a tender palpable frontal mass 16 months after he had been
ted two bony erosions (arrows in a) in his frontal and occipital bone.
row in b and c). Histological examination demonstrated Langerhans
1a.
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metabolic burst of inflammatory cells in necrosis has been
suggested to account for the false positive findings in 18F-
FDG PET [13]. As for treatment, the administration of
steroids is most frequently used in the management of early
stage RITN because steroids are capable of relieving the
inflammatory reaction and reducing cerebral edema. How-
ever, recent findings suggested that steroid therapy tempor-
arily results in symptomatic relief but fails to change the
biological process of RITN, and can also cause serious com-
plications [14]. Recently, a prospective trial demonstrated
that treatment with bevacizumab, a monoclonal antibody
against vascular endothelial growth factor, achieves a
significant improvement in symptoms and reversal of dis-
ease on imaging in the majority of patients with radiation-
induced brain necrosis [15]. Although this result is exciting,
all patients enrolled in this trial were at an early stage of
brain necrosis. Neurosurgical intervention is necessary
when RITN is at a late stage with significant mass effect
after the failure of conservative therapy. The prognosis of
RITN after surgery is favorable. Resection of necrotic
lesions not only immediately relieves the potentially life-
threatening increased intracranial pressure, but also is likely
to be effective in promptly controlling brain edema and
attenuating the progression of necrosis by removing its
inflammatory components [16].
In addition to RITN, RIS is an uncommon but severe
complication of radiotherapy in NPC patients. In gen-
eral, the estimated incidence of RIS ranges from 0.03%
to 0.30% [17,18]. For NPC, epidemiological data are
limited but two recent studies demonstrated that RIS ac-
counts for less than 0.2% of patients [19,20]. The devel-
opment of RIS is suggested to be associated with the
previous radiation dose and the genetic susceptibility of
the specific population [21-23]. RIS appears to be one of
the most intractable diseases and treatment is particu-
larly challenging. Surgical resection is still the preferred
option for RIS and total removal has been shown to be
the most significant prognostic factor. Patel et al.
demonstrated that the median overall survival was 47
months for RIS patients with gross total resection com-
pared to only 27 months for those with incomplete re-
moval [24]. Nevertheless, RIS in the head and neck is
often hard to remove completely because of its deep-
seated location around the skull base and the proximity
to vital neural and vascular structures. Without a nega-
tive surgical margin, local growth and recurrence are fre-
quently observed, and that is one of the possible reasons
why RIS in the head and neck has a worse outcome than
its counterpart in some other organs, such as the ex-
tremities [25]. In patients 23 and 24, subtotal resection
only was achieved because of the extensive invasion of
RIS to intracranial, orbital and subtemporal structures.
The role of adjuvant treatment such as radiotherapy andchemotherapy for RIS is controversial. Although radio-
therapy has a definite role in the management of pri-
mary sarcoma, it has seldom been recommended for RIS
[26,27]. The high cumulative radiation dose to adjacent
organs, inefficacy of radiation in RIS and the risk of in-
ducing another malignancy are the major concerns for
re-irradiation. But in a report by Tan, RIS demonstrated
a significant response to repeated radiation. The RIS pa-
tient described in that report achieved five-year disease-
free survival after preoperative irradiation followed by en
bloc resection of the tumor [28]. Similarly, the role of
chemotherapy for RIS is hard to assess. A few authors
have adopted regimens from primary sarcomas and ad-
ministered these for treatment of RIS. Efficacy of chemo-
therapy has been observed in some studies but was not
confirmed by others [24,29-31]. Therefore, the aggressive
removal achieved by neurosurgeons is still the mainstay
for the treatment of RIS in NPC patients, and the
efficacy of radiotherapy and chemotherapy requires
further investigation.
Coexistence of NPC and another type of tumor, such
as breast cancer, renal cancer and lymphoma, has been
episodically reported [32-34]. But synchronous NPC
with primary brain tumors has not been described in
English literature. We identified four such cases, among
which two NPC patients were simultaneously diagnosed
with glioma and two with meningioma involving the an-
terior skull base. The development of multiple primary
tumors has been suggested to be associated with the
shared risk factors of different tumor types and tumor
predisposition in individuals [35]. Epstein-Barr virus in-
fection, salt-preserved fish consumption and smoking
are well-known risk factors for NPC, but these have not
been confirmed as responsible for the etiology of glioma
and meningioma [36]. The predisposition to tumors
probably accounts for the synchronousness in these four
cases. As an example, in the case of patient 20, his sister
suffered from NPC and his son was diagnosed with
leukemia. We speculated that specific genetic alterations
made him susceptible to NPC and glioma. The initial
diagnosis was elusive for these cases because it is
complicated by the presence of NPC. In patient 19,
the primary brain tumor was initially diagnosed as a
metastasis from the NPC, and the meningioma in pa-
tient 21 was considered to be due to invasion of NPC
into the base of the skull. Without having performed
histological examination of tissues from the neurosurgi-
cal resection, these patients could have been treated as
late-stage NPC with radiotherapy and chemotherapy. If
so, these patients would have suffered from toxicity due
to inappropriate treatment.
In the current article, we reported two cases of recur-
rent NPC with the involvement of the base of the skull,
one of which was found in the CPA and the other in the
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skull base because of its anatomical features. The regions
in the skull base most frequently involved with NPC are
the pterygoid process, the base of the sphenoid bone
and the petrous apex [37]. However, spread to the CPA
is uncommon, with an estimated incidence of approxi-
mately 0.05% for primary disease and 1.0% for
recurrent cases [38]. Direct extension via the jugular
foramen, hematogenous or lymphatic metastasis, and
dissemination through cerebrospinal fluid are sug-
gested as possible mechanisms [39-41]. In addition,
minimization of the radiation dose to the brainstem in
order to protect it from radiation-induced injury dur-
ing radiotherapy for NPC may place the CPA in the
low-dose or high-dose gradient area. Therefore, the
undertreated microscopic foci may progress to a symp-
tomatic lesion in the CPA. Early diagnosis of recurrent
NPC involving the CPA is difficult because the initial
symptom of sensorineural deafness or headache in
these patients can be assumed to be the sequel of ir-
radiation and impaired function of the facial nerve may
be considered to be Bell’s palsy. Even with imaging ex-
aminations, it is challenging to diagnose the disease ac-
curately, especially when there is no recurrence in the
nasopharynx. Recurrent NPC in the CPA can extend
into the internal auditory meatus masquerading as an
acoustic neuroma [42]. In patient 25, the recurrent
disease was radiologically diagnosed as an acoustic
neuroma. We employed 18F-FDG PET to facilitate
the diagnosis. The significantly increased uptake of
18F-FDG by the lesion and neck lymph node supported
the diagnosis of a recurrence in CPA. In general,
chemotherapy and re-irradiation are recommended for
recurrent NPC. But in this case, neurosurgical removal
was first performed because of the space-occupying ef-
fect of the lesion. After surgery, this patient was
treated with radiotherapy and chemotherapy.
Mastoid recurrence of NPC is extremely unusual. Only
two cases have previously been reported [43]. Although
the mechanism of how NPC cells reach the mastoid
antrum remains unclear, the eustachian tube is extrapo-
lated to be the route. Mastoiditis and a radiation-
induced temporal bone tumor are among the differential
diagnoses. Because the treatment and prognosis of the
three diseases mentioned above are totally different, the
histological examination is critical. In patient 26, we
performed biopsy of the lesion in the mastoid antrum.
When analysis of the intra-operative frozen section sug-
gested a diagnosis of NPC, we terminated the surgical
procedure because extensive resection is not necessary
for NPC, in contrast with radiation-induced tumors, and
may potentially result in impairment of the facial nerve.
The patient then received chemotherapy followed by re-
irradiation and no recurrence has been observed.The association between Langerhans cell histiocytosis
(LCH) and different neoplasms other than NPC has
been frequently reported. Howarth et al. reported the
largest series of 27 cases of coexisting LCH with other
neoplasms, accounting for 8.6% of all LCH patients [44].
Lung cancer, hematological malignancy and endocrine
tumor were found in the group of patients. In addition,
synchronous or metachronous diagnosis of LCH with
Hodgkin’s disease has been repeatedly described in the
literature [45]. However, EG in an adult after treatment
for NPC has not previously been described. Common
etiological factors, altered immunity and genetic predis-
position were postulated as mechanisms underlying the
association between LCH and other neoplasms. For patient
27, genetic alteration suggested by the cancer predispos-
ition in his family, and immune dysfunction resulting from
NPC and its related treatment possibly accounted for the
metachronous tumors. The diagnosis was initially elusive in
this case. Multiple bone erosions in an adult patient with a
history of NPC was reminiscent of metastasis [46]. The
histological diagnosis established by neurosurgical resection
was critical for this patient because the treatment strategy
and prognosis are totally different for LCH and NPC bone
metastasis.
Conclusions
In the current retrospective study, we reported 27 NPC
patients treated in the neurosurgical department in an
NPC endemic region. These cases are uncommon but
clinically important. The initial diagnosis of intracranial
or skull lesions in NPC patients can be complicated by
the presence or history of the disease or treatment-
related complications. Initial misdiagnosis and delayed
diagnosis was found in specific patients. Medical practi-
tioners who manage NPC patients should be aware of
entities reported in the current article in order to avoid
misdiagnosis and improper treatment. In these cases,
neurosurgical interventions are necessary for the establish-
ment of histological diagnosis and planning of treatment.
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